XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
At Market Equity Offering Program
Common Stock
Common Stock
At Market Equity Offering Program
Additional Paid-in Capital
Additional Paid-in Capital
At Market Equity Offering Program
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2022     105,144,864          
Balance at beginning of period at Dec. 31, 2022 $ 92,057   $ 11   $ 746,889   $ (152) $ (654,691)
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock from at-the-market transactions, net of issuance costs (in shares)       3,535,093        
Issuance of common stock from at-the-market transactions, net of issuance costs   $ 21,795       $ 21,795    
Exercise of stock options (in shares)     8,826          
Exercise of stock options 34       34      
Vesting of restricted stock units and other stock awards (in shares)     372,291          
Stock-based compensation expense 6,407       6,407      
Other comprehensive gain (loss) 164           164  
Net loss (56,163)             (56,163)
Balance at end of period (in shares) at Mar. 31, 2023     109,061,074          
Balance at end of period at Mar. 31, 2023 64,294   $ 11   775,125   12 (710,854)
Balance at beginning of period (in shares) at Dec. 31, 2023     120,711,745          
Balance at beginning of period at Dec. 31, 2023 $ 36,904   $ 12   863,242   11 (826,361)
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock from at-the-market transactions, net of issuance costs (in shares)       1,041,201        
Issuance of common stock from at-the-market transactions, net of issuance costs   $ 5,780       $ 5,780    
Exercise of stock options (in shares) 12,117   12,117          
Exercise of stock options $ 48       48      
Vesting of restricted stock units and other stock awards (in shares)     594,067          
Stock-based compensation expense 4,660       4,660      
Other comprehensive gain (loss) (101)           (101)  
Net loss (19,306)             (19,306)
Balance at end of period (in shares) at Mar. 31, 2024     122,359,130          
Balance at end of period at Mar. 31, 2024 $ 27,985   $ 12   $ 873,730   $ (90) $ (845,667)